CN109320591A - 一种多肽oa-gl12及其应用 - Google Patents
一种多肽oa-gl12及其应用 Download PDFInfo
- Publication number
- CN109320591A CN109320591A CN201811258084.3A CN201811258084A CN109320591A CN 109320591 A CN109320591 A CN 109320591A CN 201811258084 A CN201811258084 A CN 201811258084A CN 109320591 A CN109320591 A CN 109320591A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- skin
- application
- free radical
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 56
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 53
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 49
- 230000029663 wound healing Effects 0.000 claims abstract description 7
- 231100000241 scar Toxicity 0.000 claims abstract description 6
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims abstract description 5
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims abstract description 5
- 229940099456 transforming growth factor beta 1 Drugs 0.000 claims abstract description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims description 6
- -1 Skin care item Substances 0.000 claims description 5
- 150000003254 radicals Chemical class 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 239000002537 cosmetic Substances 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 230000007760 free radical scavenging Effects 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 206010072170 Skin wound Diseases 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 13
- 230000037314 wound repair Effects 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 7
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241001510218 Odorrana andersonii Species 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000013456 study Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- LEFKSBYHUGUWLP-ACZMJKKPSA-N Asn-Ala-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LEFKSBYHUGUWLP-ACZMJKKPSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- UHPAZODVFFYEEL-QWRGUYRKSA-N Gly-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN UHPAZODVFFYEEL-QWRGUYRKSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- IOVHBRCQOGWAQH-ZKWXMUAHSA-N Ser-Gly-Ile Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O IOVHBRCQOGWAQH-ZKWXMUAHSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- KXIQQAWIPDDVOE-BPUTZDHNSA-N Trp-Pro-Cys Chemical compound O=C([C@H](CC=1C2=CC=CC=C2NC=1)N)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O KXIQQAWIPDDVOE-BPUTZDHNSA-N 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000009537 cortical lesion Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- KNMNNEPMKDJBDW-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-1-(2,6-dimethylphenoxy)propan-2-amine;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CCNC(C)COC1=C(C)C=CC=C1C KNMNNEPMKDJBDW-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种促皮肤创伤愈合的修复多肽OA‑GL12，所述多肽OA‑GL12包含的氨基酸序列如SEQ No.1所示。本发明所述皮肤创伤修复多肽可加速体表皮肤的创口愈合，减少疤痕产生，同时其具有促转化生长因子TGF‑β1生成和自由基清除活性的OA‑GL12的氨基酸序列，具有广阔的应用前景。
Description
技术领域
本发明属于生物医药领域，具体涉及一种具有皮肤创伤修复、促转化生长因子TGF-β1生成和清除自由基功能的活性多肽OA-GL12及其应用。
背景技术
近年来，从国内外相关研究可知，促创伤修复是目前临床研究的热点。皮肤是人体最大的器官，是机体内外环境的屏障，并且在机体的许多生理功能中起着关键作用，如排汗、疼痛和冷热感受等。一旦皮肤被损坏，将会引起机体内外环境失衡，继而导致感染甚至死亡等后果。皮肤的创伤修复大体包括止血、炎症反应、细胞增殖及组织重建，是一个复杂、延续的过程，传统的促创伤修复药物包括生长因子、细胞因子、免疫调节因子及植物萃取物质，但因其成本高、活性相对较低及安全问题等，至今仍未取得满意的临床效果。因此寻找新型促创伤修复药物更是迫在眉睫。值得庆幸的是，随着更多国内外的相关研究发现，生物活性多肽类分子因其高活性、高特异性及高稳定性等特点，已引起学者广泛的认可与重视。
两栖动物生活环境极其复杂，裸露的皮肤很容易受到岩石，各种微生物以及强烈的紫外线等因素造成的损伤。为了抵抗这些侵袭，两栖动物进化出了独特且高效的皮肤活性多肽防御系统。根据之前的研究报道，两栖动物皮肤分泌的小分子活性多肽种类极其丰富，且能快速促进自身皮肤修复的特性，因此，两栖动物的皮肤被视为促创伤修复多肽类药物开发潜力的巨大资源宝库。然而，到目前为止，关于两栖动物促创伤修复活性多肽的研究报道还较少。目前，我们从云南臭蛙(Odorrana andersonii)皮肤中找到一种具有高效促创伤修复活性的多肽，该多肽具有来源天然，活性高等特点。
因此，本发明提供了一种来源于云南臭蛙(Odorrana andersonii)皮肤分泌物的具有促皮肤创伤修复的活性多肽及其应用。
发明内容
本发明的第一目的在于提供一种多肽OA-GL12，所述多肽包含的氨基酸序列如SEQNo.1所示。
本发明的第二目的在于提供一种所述多肽OA-GL12促进体表皮肤创伤愈合、减少疤痕产生的应用。
本发明的第三目的在于提供一种所述多肽OA-GL12促转化生长因子TGF-β1生成的应用。
本发明的第四目的在于提供一种所述多肽OA-GL12清除自由基的应用。
本发明的第五目的在于提供一种含有所述多肽OA-GL12的产品，该产品可以为药物、护肤品、化妆品或保健品。
附图说明
图1为所述多肽OA-GL12的cDNA编码序列图。
图2为所述多肽OA-GL12的动物模型促创伤修复活性图；
图中，* P<0.05, ** P<0.01。
图3为所述多肽OA-GL12的TGF-β1的释放活性图；
图中，* P<0.05, ** P<0.01。
图4为所述多肽OA-GL12的自由基清除活性图；
图中，* P<0.05, ** P<0.01，*** P<0.001。
具体实施方式
下面结合附图对本发明作进一步的说明，但不以任何方式对本发明加以限制，基于本发明教导所做的任何变换或替换，均属于本发明的保护范围。
本发明所述多肽OA-GL12来源于云南臭蛙（Odorrana andersonii），包含的氨基酸序列如SEQ No.1所示。
本发明所述的多肽OA-GL12具有促进体表皮肤创伤愈合、减少疤痕产生的应用。同时，还具有促转化生长因子TGF-β1生成和清除自由基的应用。
利用所述多肽OA-GL12可制成具有促进皮肤创伤愈合、减少疤痕、促进转化生长因子TGF-β1生成和清除自由基等功效的药物、护肤品、化妆品或保健品。
由于本发明所述多肽OA-GL12具有来源天然、活性高、促修复能力强等特点，可用于加速体表皮肤的创口愈合，减少疤痕产生，具有广阔的应用前景。
下面将结合具体实施例，对本发明进行进一步的说明。
实施例1：多肽OA-GL12的人工合成。
（1）cDNA 合成、Illumina MiSeq 测序及数据分析。
一只云南臭蛙活体采自云南保山，用蒸馏水冲洗后并处死，剥离掉的皮肤被切成碎片，于在液氮中研磨。用RNAiso提取mRNA，并用the Absolutely mRNA Purification Kit纯化。通过SMART技术合成第一和第二条cDNA链，然后由特定的5’端及3’端引物进行PCR扩增，产物激活后交由Illumina MiSeq测序及分析。如图1所示：前提肽由58个氨基酸残基组成，由326个cDNA碱基对编码，斜体划线部分为所述多肽的成熟肽部分。
（2）人工合成。
得到的成熟肽部分GLLSGINAEWPC，交由武汉百意欣生物技术公司进行人工合成。
实施例2：多肽OA-GL12促修复活性的动物模型试验。
选体重22~25g的SPF级昆明小鼠进行实验，将小鼠随机分成3组，每组3只。首先给小鼠腹腔注射1%的戊巴比妥钠[剂量：1 µL/ g（体重）]麻醉小鼠，然后将小鼠背部毛剃除干净，并用75%的酒精消毒，最后在小鼠背部两侧用凿孔器凿出两个大小对称的孔,约8 mm×8mm大小。术后将小鼠放在加热器旁待其醒后放回饲养室正常饲养。每天两次上样，每孔每次上样约20 μL,每组的右侧分别涂抹0.1、1、10 nM的所述多肽溶液；前2组左侧分别涂抹生理盐水(Saline)；第3组左侧涂抹康复新(KFX)1 mg/mL。每隔2天拍照记录小鼠背部创伤情况，最后通过Image J 软件计算创伤修复率。
结果如图2所示：多肽的促创伤修复活性呈浓度和时间依赖性。创伤图片显示小鼠全皮层损伤模型随着时间的增长，创伤逐渐恢复，而10 nM组恢复最好。数据显示：生理盐水组的创伤修复率明显低于康复新组或者多肽组；10 nM多肽处理组的创伤修复率在第2天和第4天显著高于生理盐水组（P<0.05），在第6、8、10天极显著高于生理盐水组（P<0.01）。与对照相比，所述多肽具有较强的修复活性。
实施例3：多肽OA-GL12促转化生长因子TGF-β1释放的活性检测。
将小鼠巨噬细胞株（Raw 264.7）用含10%胎牛血清的培养基培养于含5% CO2、37°C的恒温培养箱中。取90 μL 含2×105个细胞的培养液（不含胎牛血清）加入96 孔板中，待2h细胞贴壁之后，加入10 μL不同浓度的多肽至终浓度分别为2、5、10 pM，对照组（Vehicle）加入等体积的培养基（不含胎牛血清），继续培养 12 h, 然后收集上清液，用 ELISA 方法检测上清液中TGF-β1 的含量。
由图3可知：多肽OA-GL12促TGF-β1释放的活性随着浓度的升高而增强，TGF-β1的释放量逐渐增加，与对照组相比，有显著和极显著的统计学差异。结果表明本发明所述多肽具有较强的促TGF-β1释放活性。
实施例4：多肽OA-GL12的自由基清除活性检测。
1,1-二苯基-2,-苦肼基 （DDPH）自由基清除活性检测操作步骤如下：用甲醇将DPPH 配成浓度为5×10-5 mol/L的母液避光 4°C储存备用。取190 μL DPPH储存液与 10 μL多肽溶液混匀至终浓度0.06、0.125、0.25、0.5、1 μM，室温避光反应 30 min, 之后检测OD517nm 值，等体积等浓度的维生素C（Vitamin C）作为阳性对照，等体积的蒸馏水(H2O)作为阴性对照。
DPPH自由基清除率=（A甲醇 – A样品）/A甲醇×100%。
结果如图4所示：多肽OA-GL12的DPPH自由基清除活性随着浓度的升高而增强。随着浓度的增加，多肽对DPPH自由基的清除率逐渐增大，与阴性对照组(H2O)相比，有显著性统计学差异（*** P<0.001）；与等浓度的阳性对照组（Vitamin C）相比多肽的DPPH自由基清除率明显高于Vitamin C。结果表明：本发明所述多肽OA-GL12具有较强的DDPH自由基清除活性。
SEQUENCE LISTING
<110> 昆明医科大学
<120> 一种多肽OA-GL12及其应用
<130> 2018
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 12
<212> PRT
<213> Odorrana andersonii
<400> 1
Gly Leu Leu Ser Gly Ile Asn Ala Glu Trp Pro Cys
1 5 10
Claims (5)
1.一种多肽OA-GL12，其特征在于，所述多肽包含的氨基酸序列如SEQ No.1所示。
2.一种权利要求1所述多肽OA-GL12促进体表皮肤创伤愈合、减少疤痕产生的应用。
3.一种权利要求1所述多肽OA-GL12促转化生长因子TGF-β1生成的应用。
4.一种权利要求1所述多肽OA-GL12清除自由基的应用。
5.一种含有权利要求1~4任一所述多肽OA-GL12的产品，其特征在于，所述产品为药物、护肤品、化妆品或保健品。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811258084.3A CN109320591B (zh) | 2018-10-26 | 2018-10-26 | 一种多肽oa-gl12及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811258084.3A CN109320591B (zh) | 2018-10-26 | 2018-10-26 | 一种多肽oa-gl12及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109320591A true CN109320591A (zh) | 2019-02-12 |
| CN109320591B CN109320591B (zh) | 2021-06-01 |
Family
ID=65261786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811258084.3A Active CN109320591B (zh) | 2018-10-26 | 2018-10-26 | 一种多肽oa-gl12及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109320591B (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110642924A (zh) * | 2019-10-12 | 2020-01-03 | 杨莹 | 一种皮肤保护肽om-tv16及其制备方法与应用 |
| WO2022042590A1 (zh) * | 2020-08-26 | 2022-03-03 | 四川好医生攀西药业有限责任公司 | 用于修复皮肤创伤或黏膜损伤的多肽及其应用 |
| CN114716515A (zh) * | 2022-03-31 | 2022-07-08 | 深圳深创生物药业有限公司 | 一种多肽类似物及其制备方法和应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102206264A (zh) * | 2011-04-28 | 2011-10-05 | 中国科学院成都生物研究所 | 一种景东臭蛙抗菌肽及其制备方法和用途 |
| CN102657845A (zh) * | 2012-05-31 | 2012-09-12 | 中国科学院昆明动物研究所 | 无指盘臭蛙促皮肤修复多肽ah90和cw49的应用 |
| CN108530527A (zh) * | 2018-04-23 | 2018-09-14 | 昆明医科大学 | 一种多肽oa-gl21及其提纯方法与应用 |
-
2018
- 2018-10-26 CN CN201811258084.3A patent/CN109320591B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102206264A (zh) * | 2011-04-28 | 2011-10-05 | 中国科学院成都生物研究所 | 一种景东臭蛙抗菌肽及其制备方法和用途 |
| CN102657845A (zh) * | 2012-05-31 | 2012-09-12 | 中国科学院昆明动物研究所 | 无指盘臭蛙促皮肤修复多肽ah90和cw49的应用 |
| CN108530527A (zh) * | 2018-04-23 | 2018-09-14 | 昆明医科大学 | 一种多肽oa-gl21及其提纯方法与应用 |
Non-Patent Citations (3)
| Title |
|---|
| XIAOQING CAO等: "Cathelicidin-OA1, a novel antioxidant peptide identifed from an amphibian, accelerates skin wound healing", 《SCIENTIFIC REPORTS》 * |
| YONGLI SONG等: "A short peptide potentially promotes the healing of skin wound", 《BIOSCI REP》 * |
| 赵亮 等: "抵抗素对原代培养的脐静脉内皮细胞分泌ET-1、TGF-β1的影响", 《山东医药》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110642924A (zh) * | 2019-10-12 | 2020-01-03 | 杨莹 | 一种皮肤保护肽om-tv16及其制备方法与应用 |
| CN110642924B (zh) * | 2019-10-12 | 2022-10-28 | 杨莹 | 一种皮肤保护肽om-tv16及其制备方法与应用 |
| WO2022042590A1 (zh) * | 2020-08-26 | 2022-03-03 | 四川好医生攀西药业有限责任公司 | 用于修复皮肤创伤或黏膜损伤的多肽及其应用 |
| CN114716515A (zh) * | 2022-03-31 | 2022-07-08 | 深圳深创生物药业有限公司 | 一种多肽类似物及其制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109320591B (zh) | 2021-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107619437B (zh) | 一种皮肤创伤修复肽whpp-oa1及其提纯方法与应用 | |
| CN109320591A (zh) | 一种多肽oa-gl12及其应用 | |
| KR101686399B1 (ko) | 항노화용 화장료 조성물 | |
| CN113248573B (zh) | 改善皮肤生理特性的活性肽与间充质干细胞外泌体在药品或化妆品中的应用 | |
| CN108530527B (zh) | 一种多肽oa-gl21及其提纯方法与应用 | |
| CN107075473A (zh) | 其中未分化细胞被去除的分化诱导的细胞群、其用途及其制备方法 | |
| CN111704652B (zh) | 一种抗光损伤皮肤保护活性多肽om-gl15及其应用 | |
| CN112574282A (zh) | 一种抗氧化损伤皮肤保护活性多肽rl-pp10及其应用 | |
| Lin et al. | Collagen peptides derived from Sipunculus nudus accelerate wound healing | |
| TW202031275A (zh) | 促進皮膚創傷癒合之醫藥組成物及其用途 | |
| CN104402975A (zh) | 抗衰老短肽及其制备方法 | |
| CN111759748A (zh) | 一种抗衰老肽类组合物及其应用 | |
| CN103275187B (zh) | 一种镇痛肽fi及其基因和应用 | |
| CN103819552A (zh) | 一种发形霞水母多肽生长因子及其制备方法和应用 | |
| CN110642924B (zh) | 一种皮肤保护肽om-tv16及其制备方法与应用 | |
| KR20150120426A (ko) | 갈조류 추출물, 효모 추출물 및 아스코르브산을 함유하는 화장료 조성물 | |
| La Padula et al. | Nanofat in plastic reconstructive, regenerative, and aesthetic surgery: a review of advancements in face-focused applications | |
| CN110368347A (zh) | 一种抗衰修复双层双色精华素及其制备方法 | |
| CN112480209B (zh) | 一种抗皮肤光损伤保护活性多肽rl-pl9及其应用 | |
| CN110590912A (zh) | 一种新型抗氧化活性多肽oa-vi12及其制备方法与应用 | |
| CN104031135A (zh) | 树蛙防御肽PopuDef及其基因和应用 | |
| CN102161981B (zh) | 一种重组蛋白联合诱导骨髓间充质干细胞转变为汗腺细胞的方法 | |
| CN113563419A (zh) | 一种促皮肤创伤修复活性同源二聚体多肽及其制备方法与应用 | |
| CN114644705B (zh) | 一种防护皮肤急性光损伤活性多肽及其应用 | |
| CN110078793A (zh) | 一种具有抗衰老和修复作用的多肽及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220614 Address after: 710016 B 1616, Tiandi Times Plaza, Fengcheng two road, Weiyang District, Xi'an, Shaanxi. Patentee after: Liu Jiaojiao Address before: Kunming Medical University, 1168 Chunrong West Road, Chenggong District, Kunming, Yunnan 650500 Patentee before: KUNMING MEDICAL University |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220719 Address after: 225316 floors 1-4, building 22, No. 20, Xiushui Road, pharmaceutical high tech Zone, Taizhou City, Jiangsu Province Patentee after: Jiangsu Hengrui Biomedical Technology Co.,Ltd. Address before: 710016 B 1616, Tiandi Times Plaza, Fengcheng two road, Weiyang District, Xi'an, Shaanxi. Patentee before: Liu Jiaojiao |
|
| TR01 | Transfer of patent right |